A Pre-Approval Information Exchange (PIE) Webinar, presented by Beren Therapeutics P.B.C.

This webinar provides an overview of infantile onset Niemann Pick disease type C, a rare, autosomal recessive neurodegenerative disorder caused by impaired intracellular cholesterol trafficking that leads to progressive neurologic decline and premature death, and discusses emerging clinical evidence for adrabetadex, an investigational therapy designed to re establish cholesterol trafficking. Topics include disease burden, unmet need, clinical and safety results, and managed care implications.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Mineralys Therapeutics, Inc.

This Pre-Approval Information Exchange (PIE) webinar will review the burden, pathophysiology, and unmet need in uncontrolled and treatment-resistant hypertension, including the role of aldosterone. The session will also provide an overview of lorundrostat, an investigational aldosterone synthase inhibitor, including its mechanism of action and key clinical trial data to inform healthcare decision-making.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP Market Insights Webinar.

This webinar will explore payer perspectives on hard-to-control hypertension, including ongoing unmet needs in blood pressure management, barriers to effective care, and the factors that influence current management strategies. Attendees will gain insight into payer decision-making priorities, evidence sources, and opportunities for managed care stakeholders to improve care delivery and patient outcomes.

A Science & Innovation Webinar, presented by Cytokinetics.

• Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) is a chronic, progressive condition affecting 1:200 to 1:500 individuals in the US^1,2
• Despite available standard-of-care therapies, patients may experience impaired functional capacity and disease progression, driving the need for therapies that target the underlying oHCM pathophysiology rather than symptoms alone^2-4
• This webinar will be led by Rachel Lavelle, PharmD, who brings complementary clinical and managed care perspectives on oHCM, combining deep experience in cardiology care, guideline-directed therapy implementation, and value-focused cardiovascular outcomes

An AMCP Market Insights Webinar.

This webinar will explore payer perspectives on ESR1-Mutated advanced breast cancer. Attendees will gain insight into payer decision-making priorities, evidence sources, and opportunities for managed care stakeholders to improve care delivery and patient outcomes.

11 am-12 pm ET

Unpacking the Data: The Application and Interpretation of Real-World Evidence in GLP-1 Obesity Treatment

GLP-1 agonists to treat obesity continue to challenge health plan sponsors as a major contributor to prescription drug spending, leading to widespread variation in coverage among health plans and employer groups. GLP-1 treatments for obesity hold the potential for improved health outcomes which could offset increasing prescription drug spending through reductions in medical costs. However, real-world evidence on this connection remains limited, with seemingly contradictory findings across analyses. Variation in study design and assessment contributes to these differences, creating challenges for managed care professionals seeking to leverage this evidence when making coverage decisions. This presentation will address the existing knowledge gap by reviewing the real-world evidence on GLP-1 products for obesity, exploring how variation in the design of these studies affects results, and describing how managed care decision-makers can leverage current evidence to inform GLP-1 coverage decisions. 

2-3 pm ET

Research Podium Session - Leveraging Real-World Data to Advance Managed Care Pharmacy Practice

Each year, hundreds of authors submit research abstracts to AMCP’s Annual Meeting. Accepted abstracts are presented as posters in the Expo Hall and published in a special issue of the Journal of Managed Care + Specialty Pharmacy. Top abstracts are awarded platinum ribbons and presented at the Research Podium Session.  

AMCP’s 2026 platinum abstracts had a common theme – use of real-world data to advance managed care pharmacy practice. In this Research Podium Session, authors will describe novel ways to leverage and link datasets to provide a deeper understanding of patients and outcomes.  

4-5 pm ET

Health Plan Best Practices in Psoriasis: Overcoming Access Barriers to Advanced Treatments

Sponsored and presented by Impact Education, LLC, separate registration required. Click here to register.

This activity is supported by an educational grant from Johnson & Johnson.

The psoriasis treatment landscape is rapidly evolving. Although treatment guidelines are routinely updated, ongoing innovation and the introduction of new therapies frequently render even the most current guidelines incomplete. During this symposium, expert faculty members will discuss solutions that managed care professionals can implement in their own settings to help aid in improving outcomes for patients with psoriasis. Faculty members will demonstrate the unique perspectives they bring to overall care recommendations for patients with psoriasis within a managed care setting.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Jazz Pharmaceuticals.

Gastric and gastroesophageal adenocarcinomas are often diagnosed at advanced stages with poor survival. HER2 overexpression occurs in ~20% of cases. This pre‑approval exchange reviews disease burden, current first‑line treatment, and emerging late‑stage data for zanidatamab in HER2‑positive gastroesophageal adenocarcinoma for payer evaluation. Zanidatamab‑hrii is under investigation for first‑line treatment of locally advanced/metastatic HER2+ GEA; safety and efficacy are not established.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP PA/UM LINK Group Webinar.

How are we doing as an industry as we strive to balance evidence, access, and consistency across coverage policies?   This webinar takes a deep dive into how UM practices vary across payers and how they’ve evolved from 2017–2025. Dr. James D. Chambers, PhD, MPharm, Professor at Tufts Medicine and Center for the Evaluation of Value and Risk in Health, will examine the evidence health plans cite in drug coverage policies and assess how payer criteria align with pivotal clinical trials—using cell and gene therapies as a real‑world case study.

If you haven’t had an opportunity to hear Dr Chambers- you won’t want to miss this!  And if you have, we know you have already registered!